Skip to main content
. 2012 Jun 18;13(1):48. doi: 10.1186/1465-9921-13-48

Table 1.

Baseline characteristics of the study sample and comparison with patients lost to follow-up

  Women (n = 159) Men (n = 249) Lost to follow-up (n = 69) p**
Age, mean years (SD)
62.3 (6.7)
64.2 (7.0)
66.8 (5.9)
<0.01
  FFMI, mean kg/m2 (SD)
14.8 (2.4)
18.4 (3.0)
-
 
  FMI, mean kg/m2 (SD)
10.1 (4.3)
7.3 (2.5)
-
 
  % cachectic*
31.0
27.5
37.3
0.10
Smoking habits, n(%)
 
 
 
0.32
  ex
88 (55.3)
144 (57.8)
43 (62.3)
 
  current
71 (44.7)
105 (42.2)
26 (37.7)
 
GOLD stage
 
 
 
<0.01
  II
82 (51.6)
111 (44.6)
22 (31.9)
 
  III
66 (41.5)
105 (42.2)
31 (44.9)
 
  IV
11 (6.9)
33 (13.2)
16 (23.2)
 
Hypoxemia, n(%)
 
 
 
<0.01
  PaO2 > 9 kPa
84 (61.3)
150 (64.4)
26 (44.1)
 
  PaO2 8–9 kPa
33 (24.1)
56 (24.0)
17 (28.8)
 
  PaO2 < 8 kPa
20 (14.6)
27 (11.6)
16 (27.1)
 
Exacerbations last year, n(%)
 
 
 
0.01
  0-1
126 (79.3)
214 (85.9)
50 (72.5)
 
  2+
33 (20.7)
35 (14.1)
19 (27.5)
 
Charlson Comorbidity Index
 
 
 
<0.01
  1
101 (63.5)
130 (52.2)
30 (43.5)
 
  2
40 (25.2)
59 (23.7)
15 (21.7)
 
  3
13 (8.2)
36 (14.5)
12 (17.4)
 
  4+
5 (3.1)
24 (9.6)
12 (17.4)
 
Use of inhaled steroids
 
 
 
0.19
  No
40 (25.2)
88 (35.3)
17 (24.6)
 
  Yes
119 (74.8)
161 (64.7)
52 (75.4)
 
Use of long-acting beta2 agonists
 
 
 
0.07
  No
33 (20.8)
80 (32.1)
13 (18.8)
 
  Yes
126 (79.2)
169 (67.9)
56 (81.2)
 
Use of theophyllin
 
 
 
0.02
  No
144 (90.6)
228 (91.6)
58 (84.1)
 
  Yes
15 (9.4)
21 (8.4)
11 (15.9)
 
CRP, mean ug/mL (SD)
2.4 (3.1)
2.4 (2.7)
2.5 (2.5)
0.35
TNF-α mean pg/mL (SD)
1.8 (3.4)
1.8 (3.3)
1.2 (2.5)
0.12
IL-1ß, mean pg/mL (SD)
0.8 (2.0)
1.0 (2.2)
1.0 (2.1)
0.77
IL-6, mean pg/mL (SD) 2.2 (6.8) 2.2 (5.5) 1.4 (2.7) 0.32

*defined as FFMI < 14 kg/m2 for women and <17 kg/m2 for men.

**for difference between baseline and lost to follow up; chi square for categorical variables and Kruskal Wallis test for continuous variables.